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Editorial
African trypanosomiasis
L. J. MORRISON1 & A. MACLEOD2
1Wellcome Trust Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary
and Life Sciences, University of Glasgow, Glasgow, UK, 2Wellcome Trust Centre for Molecular Parasitology, Institute of Biodiversity,
Animal Health and Comparative Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
African trypanosomiasis remains a serious health concern
across large areas of sub-Saharan Africa, despite several
decades of research. As well as causing sleeping sickness in
humans, trypanosomes are responsible for significant dis-
ease in livestock. The combination of human and livestock
disease makes these parasites a serious impediment to agri-
cultural and economic advancement in the affected areas,
an impact that combines with the obvious health concerns
to create a problem that seriously impinges at several levels
upon human wellbeing. Despite this seemingly pessimistic
summary, significant strides have been made in our under-
standing of the interactions between the host and the para-
site that drive disease and shape the course of infections.
This volume will attempt to summarise recent significant
findings, outlining the holistic way in which our under-
standing is progressing, encompassing human and livestock
disease, disease determinants in both the host and the par-
asite, and the potential that is arising for novel therapeutics
from the often neglected member of the lifecycle, the tsetse
fly. Given the emerging drug resistance in both human and
livestock licensed trypanocidal drugs and the fact that a
vaccine is unlikely for African trypanosomes, understand-
ing the disease process and the key host–parasite interac-
tions that influence this is an obvious route by which novel
interventions may be developed.
An obvious first step in this process is to comprehend
what occurs in the mammalian host when it is infected
with trypanosomes. A crucial component that has contrib-
uted significantly to our knowledge of what influences the
outcome of trypanosome infection has been the develop-
ment over the decades of a multi-faceted rodent model of
disease. Although not the ‘natural host’ of trypanosome
infections, Stefan Magez and Guy Caljon (1) review key
insights that the rodent model has enabled, and which
would have been extremely difficult if not impossible with-
out this tractable system. These include how the trypano-
some interacts and is affected by both the humoral and
innate immune responses, how human-infective trypano-
somes are able to avoid lysis by human serum (which has
the innate ability to kill all other species of African try-
panosome – this work was first pioneered in the mouse),
and the influence of tsetse saliva on the immune response
at the bite site. Boniface Namangala (2) expands on these
themes and outlines the impact of trypanosome infection
upon lymphocyte responses. While the rodent model has
undoubtedly hugely enriched our knowledge of immuno-
pathogenesis in trypanosomiasis, complementary studies in
natural hosts are a key component in confirming transla-
tion of any findings. Bruno Bucheton, Annette MacLeod
and Vincent Jamonneau (3) describe recent data from
sleeping sickness patients. These findings indicate that the
classically described progression of Trypanosoma brucei
gambiense infection leading through Stage 1 disease
(haemolymphatic) to Stage 2 symptoms (neurological) and
then death is too simplistic. They describe the diversity of
disease presentation and progression observed, discuss the
probability of ‘trypanotolerance’ (whereby the genetics of
the host plays a role in susceptibility or otherwise to try-
panosome infections, i.e., trypanotolerant hosts remain
infected but do not display the serious clinical signs dis-
played by susceptible counterparts) in humans, and review
what is currently known about possible host factors that
may contribute to this.
While a significant amount of research has much
improved our understanding from the mammalian host’s
perspective, a significant factor in disease pathology is
obviously supplied by the parasite. Genetic variation in
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the host, as outlined above, has been the foundation of a
formidable body of work that has aimed to identify host
genes and gene variants (in mice and cattle) that determine
the severity of clinical signs during trypanosome infection.
Liam Morrison (4) describes recent approaches that have
used genetic variation in T. brucei as a basis for identifying
parasite genes and gene products that influence the disease
phenotype in the host. Although this parasite-derived vari-
ation in host phenotype has long been recognised, for
example, the classical description of the human disease
caused by the subspecies of T. brucei as chronic or acute
depending on the infecting subspecies, only relatively
recently has the qualitative evaluation of the contribution
of parasite genetic variation emerged as a focus of
research. It is clear that for a holistic understanding of the
relative contribution of the parasite and host to disease
outcome, this is an aspect that will be important in the
future. This theme is extended by Peter Van den Bossche,
Simbarasha Chitanga, Justin Masumu, Tanguy Marcotty
and Vincent Delespaux (5), to the most important try-
panosome with respect to livestock morbidity and mortal-
ity in sub-Saharan Africa, Trypanosoma congolense. They
outline their previous work that describes virulence varia-
tion in field isolates of T. congolense and revisit this with
new analysis that contextualises the epidemiological influ-
ences and impact of trypanosomes and virulence. This is
done by comparing the virulence of strains from both syl-
vatic and domestic life cycles, and the authors suggest that
the relative selective forces of each system will influence
the virulence of the parasite.
Finally, John Harrington (6) describes how antimicro-
bial peptides, derived from a variety of biological sources,
may be potentially exploited to develop novel therapies
for trypanosome infections in the mammalian host. The
role that these small molecules play in the tsetse innate
immune response against trypanosomes is described. Cur-
rent knowledge of the identity and diversity of antimicro-
bial peptides is summarized, and recent studies that have
assessed the trypanocidal ability of synthetic and natural
antimicrobial peptides (from a variety of mammals as
well as fungi), in addition to that of some unconven-
tional peptides, are discussed. Antimicrobial peptides
represent an example of how a relatively neglected area
can represent a hitherto untapped resource for novel
approaches.
The collection of articles highlights much of the progress
that has been made in terms of understanding the disease
process from the perspective of the mammalian host, the
tsetse host and the parasite. They also make clear the
power and the necessity of approaches that improve our
knowledge base for all three components of the life cycle.
It is also evident that there are significant challenges to be
overcome, in terms of not only understanding fully the
basic and key host–parasite interactions that influence the
course of disease but also exploiting any findings to reduce
the burden of trypanosomiasis at an applied level.
The editors would like to thank all of the authors for
their contribution to this volume, and Mrs Emma Missen,
the co-ordinating editor. Our last note is to acknowledge
the sad passing of Peter Van den Bossche during the prep-
aration of this issue, who has contributed so much to the
understanding of trypanosome biology.
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